Tina Anderson (@Tina__Anderson) header
Tina Anderson (@Tina__Anderson) profile picture

Real Estate Professional & Stock Trader with 14 years of market experience. FINRA-registered.

Joined May 2016
Photo by Tina Anderson (@Tina__Anderson)Photo by Tina Anderson (@Tina__Anderson)Photo by Tina Anderson (@Tina__Anderson)Photo by Tina Anderson (@Tina__Anderson)
$CAPR That $2.65M debit for 10,000 contracts of $6/$2 put spreads is certainly worth watching ahead of Sunday’s PDUFA. One possible interpretation is that a large long holder is using the spreads as downside protection rather than liquidating shares ahead of a binary FDA decision. If the position covers 1M shares, the structure could provide a defined downside hedge while preserving upside exposure. It may also help manage portfolio risk and potential VaR limits. The December 18 expiration provides additional time in case the FDA timeline shifts. There is another angle: dealer hedging could create some short-term selling pressure as market makers manage their exposure. None of this confirms who placed the trade or why. But the size and timing are certainly interesting. The big question is whether this is institutional insurance ahead of the decision or a signal of something else. Sunday’s PDUFA is the event everyone is watching. 👀
1
2
547
$CAPR That $2.65M debit for 10,000 contracts of $6/$2 put spreads is certainly worth watching ahead of Sunday’s PDUFA. One possible interpretation is that a large long holder is using the spreads as downside protection rather than liquidating shares ahead of a binary FDA decision. If the position covers 1M shares, the structure could provide a defined downside hedge while preserving upside exposure. It may also help manage portfolio risk and potential VaR limits. The December 18 expiration provides additional time in case the FDA timeline shifts. There is another angle: dealer hedging could create some short-term selling pressure as market makers manage their exposure. None of this confirms who placed the trade or why. But the size and timing are certainly interesting. The big question is whether this is institutional insurance ahead of the decision or a signal of something else. Sunday’s PDUFA is the event everyone is watching. 👀
2
530
$NVDA Being a bull feels pretty lonely right now. Am I the only one buying this dip while everyone else is panic-buying Costco generators? 😂 $CRWV $INTC
1
578
$GNS Wes Christian, if you’ve been tracking the alleged naked shorting and damages, it’s time for a fresh update. The $1 billion figure from two years ago is outdated. Where do things stand today? What’s the latest estimate of the damages? We need updated numbers, supporting details, and transparency. According to Basile, Moe and Ritz are reportedly up to $23 million now. So what’s the current picture, Wes? Shareholders deserve an update. $GNS
1
2
399
$SOAR Not chasing this one, but it’s definitely on my radar. Watching closely to see how it develops. 👀
377
$GNS I genuinely hope this works out for everyone. Much love to all the bulls who have stayed the course. ❤️ I’ll make a special trip to the prayer tree tomorrow and say a prayer for all of you. God bless, and may we finally get the outcome we’ve been hoping and praying for. 🙏
344
$GNLN Anyone else noticing how well this is holding up? The resilience is catching my attention. Definitely keeping an eye on this one. 👀
242
$APLD This Louisiana meeting is delivering some important details about Delta Forge. A few highlights worth paying attention to: • The 300 MW project will consist of two 150 MW buildings, developed in four phases. • At least 200 permanent jobs are committed, paying a minimum of 150% of the state average income. • The project is expected to generate more than $32M in payroll. • APLD will begin community payments before receiving its certificate of occupancy. • The 25-year PILOT agreement includes commitments covering water, roads and community benefits. • Roughly half of the current construction workforce comes from within 100 miles. • More than 1,000 people are currently working on Delta Forge 1. The timeline is particularly interesting: Construction is underway, followed by testing, commissioning and operations. Building 1 construction is expected to begin in mid-2027. Building 2 is targeted to come online by late 2027 or early 2028. Another major detail: Management confirmed that a hyperscaler lease is already in place. The hyperscaler’s equipment is valued at approximately $3.6 billion, although the customer was not identified. The closed-loop liquid cooling system is also designed to use roughly the annual water consumption of one single-family home. What stands out to me is the scale of the commitment. This isn’t just about building data centers. APLD is putting long-term infrastructure, jobs and community investment behind the project. The hyperscaler lease, $3.6B in equipment and 300 MW development deserve attention. Delta Forge is becoming a much bigger part of the APLD story. 👀📈
268
$CAPR If Deramiocel receives a CRL, the legal fallout and finger-pointing could be enormous. But none of that will matter to the children and families who are counting on this treatment. What frustrates me most is seeing people openly cheer for a denial, as if this were just another ticker or trading opportunity. Behind this stock are real children, real families, and people hoping for a chance at a better life. This goes far beyond shareholders, management, market makers, investment banks, or the FDA. Patients should never get lost in the middle of all this. Whatever happens, let’s not lose sight of what actually matters: the families who need help. My heart goes out to them. ❤️
4
466
$OPEN This one is starting to make a pretty convincing case. Definitely worth keeping on the radar. 👀📈
1
283
$GME It’s getting harder to make sense of this market. Wars break out and stocks sell off. Peace deals are announced and stocks sell off anyway. Good news, bad news, it often feels like retail can’t win. And then there’s the dark pool activity, buy orders being routed away from lit exchanges, and the history of trading platforms restricting buying during periods of extreme volatility. Retail investors deserve transparency and a fair playing field. Who benefits when buy orders aren’t reflected in public price discovery, and why should ordinary investors have to question whether the system is working against them? This isn’t about wanting the market to go up every day. It’s about wanting a market where the rules apply equally to everyone. Enough is enough. $GME
1
306
$AMD Nowhere really feels safe in this market. Sometimes the smartest move is to sit tight, do nothing, and let the dust settle. 👀
313
$MEDS Honestly, didn’t expect this kind of strength today. Definitely catching my attention. 👀📈
242
$CAPR One additional development worth noting: On November 19, 2026, the FDA formally announced a new internal safety body within CBER, reporting directly to Karim Mikhail. Its responsibilities include independent post-market safety monitoring, labeling changes, and post-market studies covering vaccines, blood products, and cell and gene therapies. Interesting timing as we approach the anticipated Deramiocel decision. That’s all from me for now. Hopefully, tomorrow brings the news we’ve all been waiting for. If Deramiocel gets approved, we’ll have plenty to discuss. Take care, everyone! 🤞
1
1
307
$FGI This keeps grinding higher like it’s nothing. No major effort, just steady momentum. 👀📈
240
$NLST I’m not concerned about the short-term volatility. My attention is on Netlist’s earnings potential in 2027, now that Samsung and Micron are paying to license its IP. Q3 was a strong quarter: $105.1M in revenue, up 149% year over year, with $40.6M in operating income. Product revenue increased 43% to $60.2M. Samsung licensing revenue was part of those results, while Micron’s $30M quarterly payments are set to begin in Q4. With the Samsung supply agreement also in place, Netlist has an opportunity to expand both its licensing income and product sales. The broader tech weakness may continue weighing on the share price, but I believe the risk-reward is shifting. Shorts may want to reconsider their positions before market sentiment turns. When investors move back into risk assets, NLST could see a powerful return of buying interest. What matters next is how much of the Samsung and Micron licensing revenue converts into operating income, and whether the Samsung supply deal drives meaningful growth in product sales. An additional licensing agreement with SK Hynix would be another major catalyst for the 2027 outlook. I’m looking beyond today’s share price. The real story is what Netlist can deliver as these agreements begin contributing to its financial performance. $NLST
1
288
SHORT TERM: The market looks due for a solid 1–2 day bounce. Everyone in both live rooms should understand what this $VIX chart is signaling for the next couple of sessions. Keep it on your radar. 👀
200
$ANT Getting this company public was a Herculean effort, and honestly, I’m not sure what comes next. The long-term economic impact could be enormous, but the wealth distribution is already incredibly distorted. My bigger concern is regulatory capture and who ultimately gets to call the shots. The one silver lining? Competition from the other mega-cap tech players might keep things somewhat honest. A fascinating opportunity, but plenty of risks ahead. $QQQ 👀
211
$CAPR If approval comes through, hopefully management doesn’t kill the momentum with an immediate offering like SLS. Let the stock breathe first! 🤞
1
1
277
$GME This move is starting to show real signs of strength. The momentum is building, and the setup is getting harder to ignore. 👀📈
374